Matinas BioPharma Holdings, Inc. (MTNB)
| Market Cap | 327.41M |
| Revenue (ttm) | 95,833 |
| Net Income (ttm) | -22.49M |
| Shares Out | 198.91M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $1.64 |
| Previous Close | $1.56 |
| Change ($) | 0.08 |
| Change (%) | 5.13% |
| Day's Open | 1.59 |
| Day's Range | 1.51 - 1.64 |
| Day's Volume | 4,615,340 |
| 52-Week Range | 0.52 - 1.74 |
Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.
The proposed brand name for its leading pipeline drug got an important nod.
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -
– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more t...
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therape...
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript
EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort
BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...
– DSMB evaluated both safety and efficacy data in recommending cohort progression –
If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appe...
BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an...
Topline data expected first quarter 2021 Topline data expected first quarter 2021
BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B Data published...
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2020 Results - Earnings Call Transcript
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020.
On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report.
BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021 -
As of late, it has definitely been a great time to be an investor of Matinas BioPharma
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript
Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahe...
BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United St...
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2019 Results - Earnings Call Transcript
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019.
Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020
– Topline data expected Q4 2020 –
President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorde...
– Part 2 efficacy portion of EnACT expected to commence Q1 2020 –
While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.
Prospects Appear Bright for Small Drug Industry in 2020
BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...
The company announced the pricing of a public stock offering.
BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...
BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, ...
The small-cap pharma sank on an update from its top competitor.
Matinas And Amarin, And Other News And Issues: The Good, Bad, And Ugly Of Biopharma
Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings. The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared ...
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.
BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a ...
BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Ch...
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2019 Results - Earnings Call Transcript
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2019.
Liver Therapy Forum weekly digest provides an overview of therapeutics in development for hypertriglyceridemia in 2019. The focus this week is on Matinas BioPharma.
About MTNB
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The compa... [Read more...]
| Industry Biotechnology | Founded 2013 |
| CEO Jerome Jabbour | Employees 21 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol MTNB |
Analyst Forecasts
According to 6 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 3.75, which is an increase of 128.66% from the latest price.